This page shows the latest Wixela Inhub news and features for those working in and with pharma, biotech and healthcare.
Analysts predict around $250m in sales for Wixela Inhub this year. ... Mylan’s version of the drug is called Wixela Inhub and it has made it to the market ahead of rivals from the likes of Novartis’ Sandoz unit and Hikma/Vectura,
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...